About
Technology
Issues
FAQ
Links
Official Page
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.